Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2922 | Placebo (Plasma-Lyte 148) Wiki | 1.00 |
| drug1767 | Human umbilical cord derived CD362 enriched MSCs Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a prospective single-center registry with an embedded open-label single-arm clinical trial to determine the effects of standard of care treatment vs. standard of care plus AT-001 on cardiac structure and function and in-hospital survival in patients hospitalized for management of COVID-19 infection. Eligible subjects with COVID-19 infection will be identified at the time of hospital admission based on existing infection control surveillance protocols, and will have clinical data extracted from the electronic medical record to determine clinical characteristics associated with cardiac structure and function and in-hospital survival. A subset of patients with history of diabetes mellitus and/or acute hyperglycemia (any glucose measurement >126 mg/dl) and evidence of acute or chronic heart disease will be treated in an open-label fashion to receive an investigational aldose reductase inhibitor, AT-001 plus standard of care.
Description: Primary Outcome Measure for overall Registry. All clinically-derived data will be collected on a daily basis until hospital discharge, or first 30 days of hospitalization (whichever is shorter).
Measure: Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization Time: 30 daysDescription: Primary Outcome measure for Interventional Arm. All clinically-derived data will be collected on a daily basis during IP administration, with safety monitoring continuing 30 days after last dose of IP.
Measure: Incidence of Adverse Events for patients receiving AT-001 Time: 45 daysDescription: Registry + Interventional
Measure: Change in left ventricular ejection fraction Time: 30 daysDescription: Registry + Interventional
Measure: Change in left ventricular end-diastolic diameter Time: 30 daysDescription: Registry + Interventional
Measure: Change in left ventricular end-systolic diameter Time: 30 daysDescription: Registry + Interventional
Measure: Change in biomarkers of cardiac injury Time: 30 daysDescription: Registry + Interventional
Measure: Frequency of atrial fibrillation Time: 30 daysDescription: Registry + Interventional
Measure: Frequency of heart block Time: 30 daysDescription: Registry + Interventional
Measure: Frequency of non-sustained ventricular tachycardia Time: 30 daysDescription: Registry + Interventional
Measure: Frequency of sustained ventricular tachycardia Time: 30 daysDescription: Registry + Interventional
Measure: Frequency of ventricular fibrillation Time: 30 daysDescription: Interventional patients only
Measure: Proportion of subjects requiring mechanical ventilation Time: 30 daysDescription: Interventional patients only
Measure: Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports